{"id":"NCT04005716","sponsor":"BeiGene","briefTitle":"Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-22","primaryCompletion":"2023-04-19","completion":"2023-12-29","firstPosted":"2019-07-02","resultsPosted":"2025-02-28","lastUpdate":"2025-02-28"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A: Tislelizumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo + Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of tislelizumab in combination with either cisplatin or carboplatin and etoposide (Arm A), compared to placebo combined with either cisplatin or carboplatin and etoposide (Arm B), as a first-line treatment for participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.","effectByArm":[{"arm":"Arm A: Tislelizumab + Chemotherapy","deltaMin":15.5,"sd":null},{"arm":"Arm B: Placebo + Chemotherapy","deltaMin":13.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0040"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["China"]},"refs":{"pmids":["38460751","39738721","33509647"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":227},"commonTop":["Anaemia","Alopecia","Neutropenia","White blood cell count decreased","Thrombocytopenia"]}}